–Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”)...
Cybin Inc. (NYSE: CYBN) announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for CYB004,...
Explore how psychedelic-assisted therapy, particularly with psilocybin, offers new, promising avenues for treating nicotine and other addictions.
Highlights: Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid...
Source: Streetwise Reports 01/17/2024 ATAI Life Sciences N.V. has announced that it is investing in psychedelic treatments for Major Depressive...
Q1 Fiscal 2024 Highlights All financial results are reported in Canadian dollars unless otherwise stated. VANCOUVER, BC, Jan. 15, 2024 /CNW/ – Numinus...
Q1 Fiscal 2024 Highlights All financial results are reported in Canadian dollars unless otherwise stated. VANCOUVER, BC, Jan. 15, 2024 /CNW/ – Numinus...
-Intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as...
Toronto-based PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is expecting to get full approval from the U.S. Food and Drug Administration (FDA) ...
–Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two...